Boardroom Alpha
Start trial
10-Q primary document
MSTR · Quarterly Report (Form 10-Q) · Filed August 5, 2025

Strategy Inc — 10-Q exhibit

mstr-ex3_12.htm
Strategy Inc on Boardroom Alpha
EX-3.12

 

Exhibit 3.12

CERTIFICATE OF VALIDATION

OF

MICROSTRATEGY INCORPORATED

PURSUANT TO SECTION 204 OF

THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE

August 1, 2025

MicroStrategy Incorporated, a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Company”), does hereby certify as follows:

1.
The Company has ratified one or more defective corporate acts (as defined in Section 204(h) of the General Corporation Law of the State of Delaware (the “DGCL”)) that would have required the filing of a certificate under Section 103 of the DGCL.
2.
Such defective corporate acts have been ratified in accordance with Section 204 of the DGCL.
3.
No certificate with respect to such defective corporate act was filed with the Delaware Secretary of State.
4.
A Certificate of Increase of the 10.00% Series A Perpetual Strife Preferred Stock of the Company (the “Certificate of Increase”) was previously filed with the Secretary of State of the State of Delaware on July 25, 2025, and a change to the date and time of the effectiveness of the Certificate of Increase is required to give effect to the defective corporate acts.
5.
A certificate containing all of the information that would be required under Section 151(g) of the DGCL to give effect to the defective corporate act, is attached hereto as Exhibit A and incorporated herein by reference. Such certificate shall be deemed to have become effective as of 6:00 a.m., Eastern Time, on May 22, 2025.

* * *

 

 

IN WITNESS WHEREOF, the Company has caused this Certificate of Validation to be executed by its duly authorized officer on the date first written above.

 

MicroStrategy Incorporated

 

 

By:

/s/ Andrew Kang

Name:

Andrew Kang

Title:

Executive Vice President and Chief Financial Officer

 

[Certificate of Validation (10.00% Series A Perpetual Strife Preferred Stock)]

 

Exhibit A

CERTIFICATE OF INCREASE

OF

10.00% SERIES A PERPETUAL STRIFE PREFERRED STOCK

OF

MICROSTRATEGY INCORPORATED

MicroStrategy Incorporated, a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Company”), does hereby certify that, pursuant to the authority conferred upon the Board of Directors of the Company by the Second Restated Certificate of Incorporation of the Company, as amended, the Board of Directors of the Company has adopted a resolution authorizing and directing the increase in the number of authorized shares designated as 10.00% Series A Perpetual Strife Preferred Stock of the Company to 33,200,000 shares.

* * *

A-1

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer